Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
pf-07329640 Colorectal Cancer	Pfizer	P1	C (36)
pf-07329640 Non-Small Cell Lung Carcinoma	Pfizer	P1	C (36)
pf-07799544 Non-Small Cell Lung Carcinoma	Pfizer	P1	C (36)
pf-07921585 Colorectal Cancer	Pfizer	P1	C (36)
pf-08032562 Colorectal Cancer	Pfizer	P1	C (36)
pf-08046032 Non-Small Cell Lung Carcinoma	Pfizer	P1	C (36)
pf-08046876 Pancreatic Neoplasm	Pfizer	P1	C (36)
Maplirpacept Fallopian Tube Cancer	Pfizer	P1/2	C (36)
Maplirpacept Ovarian Cancer	Pfizer	P1/2	C (35)
Sasanlimab Head And Neck Squamous Cell Carcinoma	Pfizer	P1	D (31)
Sasanlimab Urothelial Carcinoma	Pfizer	P1	D (31)
Sasanlimab Sarcoma	Pfizer	P1	D (30)
fx-1006a Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype	Pfizer		D (30)
fx-1006a Peripheral Neuropathy	Pfizer		D (30)
fx-1006a Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)	Pfizer		D (30)
Lutetium-177 Castration-Resistant Prostate Carcinoma	Pfizer		D (30)
Lutetium-177 Metastatic Prostate Carcinoma	Pfizer		D (30)
Sasanlimab Advanced or Metastatic Solid Tumors	Pfizer	P1	D (28)
Sasanlimab Urinary Bladder Carcinoma	Pfizer	P1	D (28)
Sasanlimab Pancreatic Ductal Adenocarcinoma	Pfizer	P1	D (28)
Sasanlimab Classic Hodgkin Lymphoma	Pfizer	P1	D (28)
Sasanlimab Colorectal Carcinoma	Pfizer	P1	D (28)
Sasanlimab Colorectal Neoplasm	Pfizer	P1	D (28)
Sasanlimab Diffuse Large B-Cell Lymphoma	Pfizer	P1	D (28)
Sasanlimab Gastroesophageal Junction Adenocarcinoma	Pfizer	P1	D (28)

Showing 426 to 450 of 461 assets

PreviousPage 18 of 19Next